Kalaris (NASDAQ: KLRS) will present Phase 1 clinical data for TH103 at the Macula Society Annual Meeting, Feb 25-28, 2026 in San Diego.
The Feb 26 presentation by Dean Eliott, MD will cover safety, tolerability, pharmacokinetics and early efficacy after intravitreal dosing in treatment‑naive neovascular AMD.
In the Jan 29 session, KLRS declined 2.65%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement highlights the upcoming presentation of Phase 1 clinical data for TH103 in treatme...
Analysis
This announcement highlights the upcoming presentation of Phase 1 clinical data for TH103 in treatment‑naïve neovascular AMD at a selective Macula Society forum. It follows prior positive Phase 1a results and recent financing intended to advance TH103. Investors may focus on safety, pharmacokinetics, and early efficacy signals shared at the meeting, and how they frame the ongoing Phase 1b/2 program and the company’s strategy around its lead retinal candidate.
Key Figures
Phase:Phase 1Conference edition:49th Annual MeetingMeeting dates:February 25–28, 2026+2 more
Phase
Phase 1
TH103 first-in-human clinical study
Conference edition
49th Annual Meeting
Macula Society meeting where TH103 data will be presented
Meeting dates
February 25–28, 2026
Macula Society Annual Meeting schedule in San Diego
Appointment of new CFO to support financing and clinical advancement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase 1, vegf, pharmacokinetics, intravitreal, +2 more
6 terms
phase 1medical
"clinical data from its Phase 1 study of TH103 will be presented"
Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.
vegfmedical
"engineered by VEGF scientific pioneer Dr. Napoleone Ferrara"
Vascular endothelial growth factor (VEGF) is a naturally occurring protein that signals the body to grow new blood vessels, like a fertilizer prompts plants to sprout. It matters to investors because drugs that block or mimic VEGF can dramatically change outcomes for cancers and eye diseases, making them major drivers of clinical trial results, regulatory approvals, market value and future revenue potential for biopharma companies.
pharmacokineticsmedical
"The presentation will include safety, tolerability, pharmacokinetics and early efficacy"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
intravitrealmedical
"following intravitreal administration of TH103 in patients"
An intravitreal treatment is one given by injecting medicine directly into the gel-like center of the eye, delivering drugs straight to the site of retinal disease rather than through pills or eye drops. Investors care because this delivery method affects development costs, regulatory review, clinical risk, manufacturing and distribution complexity, and reimbursement — all factors that influence a therapy’s commercial potential.
A progressive eye disease in older adults where abnormal blood vessels grow beneath the central retina and leak fluid or blood, quickly damaging sharp central vision used for reading and recognizing faces. For investors, it matters because it creates ongoing demand for medical treatments, diagnostics and follow-up care, and outcomes hinge on clinical trial results, regulatory approvals and reimbursement decisions that can sharply affect the value of companies developing therapies — like a chronic market need driven by a high-impact illness.
hspgmedical
"TH103, a Dual-Targeting VEGF and HSPG Inhibitor"
Heparan sulfate proteoglycans (HSPGs) are large molecules found on cell surfaces and in connective tissue that act like molecular Velcro, helping cells stick together, communicate, and control the movement of signaling molecules. Investors track HSPGs because they play a role in disease processes and drug targeting—changes or therapies that affect HSPGs can alter how a treatment works, influence clinical trial outcomes, and affect the commercial prospects of biotech and pharmaceutical investments.
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California.
TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal administration of TH103 in patients with treatment-naive neovascular age-related macular degeneration. The data will be presented during a scientific session attended by leading retinal specialists and clinical investigators.
Presentation Details:
Title: First-in-Human Evaluation of TH103, a Dual-Targeting VEGF and HSPG Inhibitor: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD
Speaker: Dean Eliott, MD, S.E. Gragoudas Professor of Ophthalmology, Harvard Medical School, Director Emeritus of Retina Service, Massachusetts Eye & Ear Infirmary
Date: Thursday, February 26, 2026
Time: 8:15 am PT
Session: Neovascular AMD I: Clinical Trials
Location: Southpointe Ballroom, Hotel Del Coronado, San Diego, CA
The Macula Society Annual Meeting is a highly selective, invitation-only forum where internationally recognized retinal experts convene to present and critically evaluate emerging clinical data and novel therapeutic strategies in retinal vascular and macular disease.
AboutKalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Kalaris (KLRS) present TH103 Phase 1 data at the Macula Society meeting?
Kalaris will present on February 26, 2026 at 8:15 am PT. According to Kalaris, the presentation is part of the Neovascular AMD I: Clinical Trials session at the Hotel Del Coronado in San Diego.
What Phase 1 TH103 results will Kalaris (KLRS) report at the Feb 26, 2026 presentation?
Kalaris will report safety, tolerability, pharmacokinetics and early efficacy outcomes from the Phase 1 study. According to Kalaris, the data reflect intravitreal administration in treatment‑naive neovascular age‑related macular degeneration patients.
Who is presenting Kalaris (KLRS) TH103 data at the Macula Society Annual Meeting?
Dean Eliott, MD will present the TH103 Phase 1 findings on behalf of Kalaris. According to Kalaris, he is S.E. Gragoudas Professor of Ophthalmology and Director Emeritus of Retina Service, Massachusetts Eye & Ear.
What is TH103 and how is Kalaris (KLRS) describing its mechanism at the 2026 Macula Society talk?
TH103 is described as a dual‑targeting VEGF and HSPG inhibitor engineered for enhanced VEGF inhibition and increased intraocular retention. According to Kalaris, it was engineered by VEGF pioneer Dr. Napoleone Ferrara.
Where and in which session will Kalaris (KLRS) present TH103 Phase 1 data at the Feb 2026 meeting?
The presentation is in the Neovascular AMD I: Clinical Trials session on Feb 26, 2026 at the Southpointe Ballroom, Hotel Del Coronado. According to Kalaris, the session gathers leading retinal specialists and investigators.
